Industry news, page-388

This is the perfect decision for IHL and I’d wager the company agrees.

The greatest commercial advantage IHL has is a highly restrictive environment for psychedelics. This creates a high barrier of entry to new players and creates a run way for an advanced company like IHL to develop and protect their IP. The last thing you want at the moment is a deregulated system that allows “bad apples” to attempt to monitize a sector before the science is mature.

It’s a sensible decision and ensures that money is efficiently invested into the scientific development of the sector, companies like IHL partnering with real scientists like Dr Liknaitzky.

@Badvet73 IMO this impacts the company positively.